Using CRISPR/Cas9 to Model Stem Cell Organization and Dynamics

Register Now
*Required
Join our live webinar with Dr. Ruwanthi Gunawardane, Director of Stem Cells and Gene Editing at the Allen Institute for Cell Science, as she discusses the application of CRISPR/Cas9 to create a dynamic visual model of human induced pluripotent stem (hiPS) cell organization.

Director of Stem Cells and Gene Editing
Allen Institute for Cell Science
Live Webinar - Using CRISPR/Cas9 to Model Stem Cell Organization and Dynamics

Wednesday, August 23, 2017 - 10AM PDT | 1PM EDT | 6PM BST

If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.


Topics
  • Creation of a dynamic visual model of hiPS cell organization through the endogenous labeling of major cellular organelles with a fluorescent protein
  • Overview of the CRISPR/Cas9 methodologies used for endogenous gene tagging, screening for precise editing, and cell biological and genomic quality control
  • An unprecedented clarity in live cell imaging provided by the endogenous tagging of hiPS cells
  • Potential applications of the Allen Institute's hiPS cell lines for basic science and disease modeling
Ruwanthi (Ru) Gunawardane, PhD, is the director of stem cells and gene editing at the Allen Institute for Cell Science, where a multi-disciplinary, team-science approach is used to study the fundamentals of cell behavior. Ru leads a group of researchers creating a collection of high-quality gene edited stem cell lines that are used by the institute to study cell organization and activities through live cell imaging and are also made available to the research community. Ru joined the Allen Institute after spending 5 years at Amgen, where she developed assays to screen for novel therapeutics in oncology, inflammation, and cardiovascular diseases and help advance the early drug discovery pipeline. Prior to Amgen, Ru worked at Ambit Biosciences as part of a small team of scientists that identified and characterized AC220, a potent FLT3 kinase inhibitor that is currently in phase 3 trials for AML. Ru obtained her PhD in Biology from Johns Hopkins University, where she studied microtubule nucleation in the Drosophila and Xenopus model systems. She conducted her postdoctoral work at the Harvard Medical School, where she studied cell migration and invasion in mammary epithelial cells using 3D tissue culture model systems as a model for breast cancer progression.

This webinar is part of our webinar series in the Pluripotent Learning Lounge, where key figures in the hPSC field discuss their recent research findings.